Abstract
The pleiomorphic adenoma gene 1 (PLAG1) gene is activated in a subset of pleomorphic adenomas of the salivary gland by gene fusion. Germ‑line mutation in cylindromatosis (CYLD), a tumor suppressor gene, causes familial cylindromatosis and Brook‑Spiegler syndrome. In the present study, aberrations in PLAG1 and CYLD were investigated in adenoid cystic carcinoma (ACC) of the salivary gland. Reverse‑transcription PCR and PCR direct sequencing were performed to detect gene fusion of PLAG1 and mutation of CYLD in 34 ACC tissues. No PLAG1 fusion was detected in ACC. However, silent mutation of CYLD was detected in 2 cases of ACC, but no missense mutation was detected in ACC. These results suggest that PLAG1 and CYLD do not play a role in ACC tumorigenesis.
Introduction
Adenoid Cystic Carcinoma (ACC) is a rare but highly malignant salivary gland tumor. While it grows slowly, it is notoriously difficult to treat because it often infiltrates nerves and recurs years later. To develop better molecular-targeted therapies, scientists need to identify the specific genetic "glitches" (mutations or gene fusions) that cause these cells to turn cancerous.
ACC shares striking physical characteristics with two other conditions: Pleomorphic Adenoma (PA), often driven by fusions of the PLAG1 gene, and Cutaneous Cylindroma, caused by mutations in the CYLD tumor suppressor gene. In fact, ACC was historically called "cylindroma" because of these morphological similarities. This study aimed to determine if these "look-alike" tumors also share the same genetic drivers.
Methods
The team analyzed 34 archival paraffin-embedded tissue samples of ACC from the Pathology Center of Oita University Hospital. They employed three main techniques to hunt for genetic errors:
- RT-PCR (Reverse-Transcription PCR): Used to detect gene fusions between PLAG1 and four known fusion partners (CTNNB1, CHCHD7, LIFR, and TCEA1).
- SSCP (Single Strand Conformational Polymorphism): A screening method used to detect mutations in the CYLD gene by observing how single-stranded DNA folds and moves through a gel.
- Direct Sequencing: Used to identify the exact nature of any mutations detected during the SSCP screening.
Results
Absence of PLAG1 Gene Fusions
The investigation into PLAG1 activation via gene fusion yielded entirely negative results. None of the 34 ACC cases showed evidence of fusion transcripts between PLAG1 and its common partners, suggesting that the PLAG1 driver defining PA is absent in ACC.
Silent Mutations in CYLD
While screening for CYLD mutations, the researchers identified two cases (5.8%) with genetic alterations. However, direct sequencing revealed these to be silent mutations (synonymous substitutions). This means the DNA sequence changed, but the resulting amino acid sequence of the protein remained exactly the same.
Discussion
The most significant takeaway is that tumors can look nearly identical under a microscope (histology) but have completely different genetic engines. Even though ACC and PA both involve epithelial and myoepithelial cells, the PLAG1 driver is not a factor in ACC. Similarly, the "silent" nature of the CYLD changes indicates they are likely passenger events rather than drivers of the cancer.
By ruling out PLAG1 and CYLD, the study reinforces the idea that ACC is a genetically distinct entity. While the study was limited to common fusion partners and a sample size of 34, the results strongly suggest that future research and therapy should focus on other pathways, such as the MYB-NFIB translocation.
Conclusion
Neither PLAG1 activation nor CYLD inactivation appears to be a requirement or a common feature of ACC tumorigenesis. These findings clarify that morphological similarity does not imply shared molecular pathogenesis in salivary gland malignancies.
Summary updated